GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codexis Inc (NAS:CDXS) » Definitions » Cyclically Adjusted PB Ratio

Codexis (Codexis) Cyclically Adjusted PB Ratio : 1.80 (As of Apr. 27, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Codexis Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Codexis's current share price is $2.66. Codexis's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $1.48. Codexis's Cyclically Adjusted PB Ratio for today is 1.80.

The historical rank and industry rank for Codexis's Cyclically Adjusted PB Ratio or its related term are showing as below:

CDXS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.04   Med: 7.79   Max: 27.7
Current: 1.79

During the past years, Codexis's highest Cyclically Adjusted PB Ratio was 27.70. The lowest was 1.04. And the median was 7.79.

CDXS's Cyclically Adjusted PB Ratio is ranked worse than
53.44% of 640 companies
in the Biotechnology industry
Industry Median: 1.715 vs CDXS: 1.79

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Codexis's adjusted book value per share data for the three months ended in Dec. 2023 was $1.239. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.48 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Codexis Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Codexis's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codexis Cyclically Adjusted PB Ratio Chart

Codexis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.48 15.03 21.57 3.18 2.06

Codexis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.18 2.80 1.88 1.27 2.06

Competitive Comparison of Codexis's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Codexis's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Codexis's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Codexis's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Codexis's Cyclically Adjusted PB Ratio falls into.



Codexis Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Codexis's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.66/1.48
=1.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Codexis's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Codexis's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.239/129.4194*129.4194
=1.239

Current CPI (Dec. 2023) = 129.4194.

Codexis Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.946 99.695 1.228
201406 0.755 100.560 0.972
201409 0.638 100.428 0.822
201412 0.665 99.070 0.869
201503 0.542 99.621 0.704
201506 0.425 100.684 0.546
201509 0.578 100.392 0.745
201512 0.567 99.792 0.735
201603 0.395 100.470 0.509
201606 0.478 101.688 0.608
201609 0.554 101.861 0.704
201612 0.463 101.863 0.588
201703 0.279 102.862 0.351
201706 0.634 103.349 0.794
201709 0.457 104.136 0.568
201712 0.508 104.011 0.632
201803 0.308 105.290 0.379
201806 0.982 106.317 1.195
201809 1.016 106.507 1.235
201812 1.041 105.998 1.271
201903 0.939 107.251 1.133
201906 1.703 108.070 2.039
201909 1.756 108.329 2.098
201912 1.792 108.420 2.139
202003 1.679 108.902 1.995
202006 1.603 108.767 1.907
202009 1.533 109.815 1.807
202012 2.646 109.897 3.116
202103 2.539 111.754 2.940
202106 2.519 114.631 2.844
202109 2.608 115.734 2.916
202112 2.525 117.630 2.778
202203 2.429 121.301 2.592
202206 2.435 125.017 2.521
202209 2.349 125.227 2.428
202212 2.200 125.222 2.274
202303 1.889 127.348 1.920
202306 1.778 128.729 1.788
202309 1.310 129.860 1.306
202312 1.239 129.419 1.239

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Codexis  (NAS:CDXS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Codexis Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Codexis's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Codexis (Codexis) Business Description

Industry
Traded in Other Exchanges
Address
200 Penobscot Drive, Redwood, CA, USA, 94063
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products. The firm's products and services include Screening and Evolution services, Enzymes, Screening Kits. It also develops protein engineering and biocatalyst platforms such as Codeevolver, Ketoreductases, Transminases, Imine reductases, etc. The company operates in two business segments namely Performance Enzymes and Novel Biotherapeutics. It generates maximum revenue from the Performance Enzymes segment. Geographically, it derives a majority of revenue from the APAC.
Executives
Byron L Dorgan director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Kevin Norrett officer: Chief Operating Officer C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Margaret Nell Fitzgerald officer: See Remarks ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Sriram Ryali officer: Chief Financial Officer C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Stephen George Dilly director, officer: See Remarks C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
John J Nicols director, officer: President and CEO ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801
H Stewart Parker director
Rahul Singhvi director 246 HOLLY DRIVE, CHALFONT PA 18914
Dennis P Wolf director 1101 EAST MEADOW DR, PALO ALTO CA 94303
Patrick Y Yang director C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990
Bernard J Kelley director
Esther Martinborough director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Jennifer Aaker director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Alison Moore director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Thomas R Baruch director 1 LETTERMAN DRIVE, BUILDING C, SUITE CM500, SAN FRANCISCO CA 94129